| abstract |
The invention relates to quinazoline derivatives of formula (I) [wherein: Y<1> represents -O-, -S-, -CH2-, -SO-, -SO2-, -NR<5>CO-, -CONR<6>-, -SO2NR<7>-, -NR<8>SO2- or -NR<9>- (wherein R<5>, R<6>, R<7>, R<8> and R<9> each independently represents hydrogen, alkyl or alkoxyalkyl); R<1> represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, alkyl, alkoxy, alkylthio, amino or alkylamino. R<2> represents hydrogen, hydroxy, halogeno, alkyl, alkoxy, trifluoromethyl, cyano, amino or nitro; m is an integer from 1 to 5; R<3> represents hydroxy, halogeno, alkyl, alkoxy, alkanoyloxy, trifluoromethyl, cyano, amino or nitro; R<4> represents a group which is or which contains an optionally substituted pyridone, phenyl or aromatic heterocyclic group] and salts thereof; processes for their preparation and pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis. |